GlassScriptPhysician profile
Thomas J Lewis
NPI 1760478192
$8,793.50
in general payments reported to CMS, 2019-2025
36 companies · $1,854 in 2025
The $1,854 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $879 · 2020: $469 · 2021: $939 · 2022: $1,536 · 2023: $1,289 · 2024: $1,828 · 2025: $1,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,943 · Education: $27.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,943.49 |
| Education | $27.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,950.68 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $744.73 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $701.06 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $660.08 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Gilead Sciences, INC. | $427.69 | 2019-2024 | |
| Genzyme Corporation | $382.26 | 2022-2025 | |
| Pfizer INC. | $321.60 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $164.14 | 2023-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $159.90 | 2021-2023 | |
| Lilly USA, LLC | $110.68 | 2024-2025 | Omvoh |
| Celgene Corporation | $106.91 | 2021-2024 | Zeposia |
| Celltrion USA INC. | $88.64 | 2024-2025 | Vegzelma, Zymfentra |
| Qol Medical, LLC | $88.26 | 2019-2025 | Sucraid |
| Shionogi INC | $87.84 | 2019 | |
| Madrigal Pharmaceuticals | $80.39 | 2024-2025 | Resmetirom, Rezdiffra |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $79.60 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $71.15 | 2024-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $67.37 | 2020-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $51.68 | 2019-2022 | |
| Viiv Healthcare Company | $51.36 | 2019-2024 | Rukobia |
| Ambu INC. | $41.52 | 2021 | |
| Aimmune Therapeutics, INC. | $40.41 | 2025 | Zenpep |
| Micro-Tech Endoscopy USA, INC. | $36.24 | 2024 | Guidewires |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.98 | 2023 | Cyltezo |
| Endo Pharmaceuticals INC. | $29.25 | 2019-2020 | |
| Immedica Pharma US, INC. | $24.22 | 2024 | |
| Astellas Pharma US INC | $23.58 | 2025 | Cresemba |
| Ipsen Biopharmaceuticals, INC | $22.93 | 2025 | Iqirvo |
| Mauna Kea Technologies, INC. | $21.68 | 2025 | |
| Shire North American Group INC | $20.56 | 2019 | |
| Theratechnologies INC. | $20.24 | 2022 | |
| Daiichi Sankyo INC. | $19.83 | 2022 | |
| La Jolla Pharmaceutical Company | $19.58 | 2024 | Xacduro |
| Ardelyx, INC. | $18.60 | 2024 | Ibsrela |
| Mayne Pharma Commercial LLC | $15.02 | 2019 | |
| Boston Scientific Corporation | $13.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.